|Bid||8.00 x 3000|
|Ask||8.01 x 2200|
|Day's Range||7.71 - 8.71|
|52 Week Range||5.20 - 22.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 26, 2017 - Oct 30, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.25|
NEW YORK, Aug. 14, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Acushnet ...
NEW YORK, NY / ACCESSWIRE / August 10, 2018 / Portola Pharmaceuticals were deep in the red on Thursday after reporting second quarter results that revealed revenue and earnings miss. Idera Pharmaceuticals shares were rising after announcing that the company would be a part of a fireside chat in NYC next week. The company also reported second quarter results last week that revealed a positive earnings surprise.
Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that the company will participate in a fireside chat, led by Vincent Milano Idera’s Chief Executive Officer at the 2018 Wedbush PacGrow Healthcare Conference on Tuesday, August 14, 2018 at 10:20 a.m. Eastern Time at the Parker Hotel in New York City. The words “believes,” “anticipates,” “estimates,” “plans,” “expects,” “intends,” “may,” “could,” “should,” “potential,” “likely,” “projects,” “continue,” “will,” and “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.
BioCryst (Nasdaq: BCRX) has raised $57.5 million in a public offering of its common stock, according to the company, with the underwriters’ option to purchase additional shares exercised in full. BioCryst, based in Research Triangle Park, said Monday that the company has been granted Fast Track Designation by the U.S. Food and Drug Administration for its product to prevent angioedema attacks in patients with hereditary angioedema, or HAE. Proceeds of the company’s public offering will be used for further development of that product candidate – known as BCX7353 – as well as for other corporate purposes, according to BioCryst.
A key drug for BioCryst Pharmaceuticals (Nasdaq: BCRX) is now on the fast track, according to the U.S. Food and Drug Administration amid its shift to a standalone strategy. BioCryst, based in Research Triangle Park, said Monday that it has been granted Fast Track Designation by the FDA for a product designed to prevent angioedema attacks in patients with hereditary angioedema.
Idera (IDRA) delivered earnings and revenue surprises of 26.25% and -9.44%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The Cambridge, Massachusetts-based company said it had a loss of 59 cents per share. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...
Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today reported its financial and operational results for the second quarter ended June 30, 2018. “The body of data that we have generated with tilsotolimod continues to demonstrate the potential positive difference this drug can make in patients who have not benefited from existing immuno-therapy. Our mission from here is to explore the entirety of the opportunity both in melanoma and additional tumor types in order that we can offer hope to as many patients as possible,” continued Milano.
Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, today announced that its Board of Directors has approved a one-for-eight reverse stock split of its common stock that will be effective at 5:00 pm Eastern Time today. Beginning with the opening of trading on July 30, 2018, the Company’s common stock will trade on the Nasdaq Capital Market on a split-adjusted basis under a new CUSIP number 45168K405. As previously disclosed, at the Company’s Annual Meeting of Stockholders held on June 20, 2018, the Company’s stockholders approved a proposal authorizing the Company’s Board of Directors to effect a reverse stock split by a whole number ratio of not less than one-for-four and not more than one-for-eight.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 16) Arcus Biosciences Inc (NYSE: RCUS ) BioLife Solutions Inc (NASDAQ: ...
Idera Pharmaceuticals, Inc. (IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for the treatment of cancer, is providing an update on the company’s corporate strategy and outlook following the recent termination of its proposed merger with BioCryst Pharmaceuticals. Vincent Milano, Idera’s Chief Executive Officer stated, “Today, we advance the next chapter of our company’s future with a clear picture of our mission, which is to ultimately deliver tilsotolimod to as many patients suffering from cancer as we possibly can.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 11) AC Immune SA (NASDAQ: ACIU ) Arbutus Biopharma Corp (NASDAQ: ...
Idera shareholders voted in favor of the deal. The Chester County company will get $6M as a result of the termination.
The Cambridge-based immunology biotech's future is murky after a planned merger with drug developer BioCryst fell through this week.
Biogen's results from a phase II study in the much-pursued Alzheimer's disease was all over the biotech sector last week.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on July 10) Bio-Rad Laboratories, Inc. (NYSE: BIO ) BioXcel Therapeutics ...
There will be no deal as shareholders of Research Triangle Park-based BioCryst Pharmaceuticals have blocked the company’s proposed merger with Exton, Pennsylvania-based Idera Pharmaceuticals.
Inc. called off merger plans Tuesday after BioCryst shareholders voted against the proposal, triggering a $6 million penalty to be paid to Idera. Some BioCryst shareholders, including Great Point Partners LLC and RA Capital Management LLC, had publicly objected to the merger plan and noted that they intended to vote against it.
MARKET PULSE Shares of BioCryst Pharmaceuticals Inc. (bcrx) and Idera Pharmaceuticals Inc. (idra) were active in the extended session Tuesday following a brief halt after BioCryst shareholders voted down a merger between the two drug companies.
Idera Pharmaceuticals, Inc. (IDRA) announced today that the Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) entered into by and among Idera and BioCryst on January 22, 2018, has been terminated. The Merger Agreement was terminated following the July 10, 2018 special meeting of BioCryst stockholders at which BioCryst’s stockholders voted against the proposed mergers. Separately, a majority of Idera’s stockholders voted in favor of the adoption of the Merger Agreement at a special meeting of Idera stockholders, also held on July 10, 2018.